about
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.Immunological alterations in hepatitis C virus infection.Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects.Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis.NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis.Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.Models for non-alcoholic fatty liver disease: a link with vascular risk.Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.TACE versus TAE as therapy for hepatocellular carcinoma.Implication of normal liver enzymes in liver disease.Fibrosis in chronic viral hepatitis.Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?Clinical implications of the hyperdynamic syndrome in cirrhosis.Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.Why do I treat my patients with mild hepatitis C?Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient.Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation.The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis.Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis.Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis.
P50
Q30402192-0A16CC2E-3D0B-4ABA-909B-4A5AD211ACCEQ33412382-5417C79C-EC6F-404E-A962-80673B63A98CQ33703634-D9ED419E-2A4D-431C-AC71-A41A6B81E215Q33866324-EA69C1EA-7BE3-4393-9532-F5B189C4FA60Q34164776-8D183DA9-2127-471A-BBF1-FA688D0B4E25Q34497297-31925BED-0935-4684-96EB-FDCA9DDA80A9Q34934407-9E1C491C-8CE7-4D43-BDB4-F70260E8B734Q35412591-3FE18936-FC3B-4735-B523-2244CDAAE53EQ35930570-16410F9E-9BBB-49B6-A816-5A93BB71EC18Q37090241-7329A84E-701C-4C66-8811-0F29971161BFQ37116189-D1D2A002-72F1-4231-BAC8-7F442AE66277Q37233133-498AEA37-5345-4A0A-AA3C-AA23C4A81844Q37300023-121C7013-0967-4F8F-B4F1-F2FFB8C1B2E2Q37572860-745B2D3E-EECF-434D-B356-DD7A2CCA7D32Q37865862-F8D20C05-9CBE-4FEC-96FE-4B17BDE511B2Q38174255-E7351A2F-1F2A-41C9-A11A-EBEF1C5BCF3EQ38253245-B499601B-3FA7-44DA-BF86-0B98AE44FC21Q38522791-2E6A3DEF-D742-4CA1-B867-E5AA8DEE6C29Q38632730-E4DB54AF-7CD8-4ED5-8021-84A926EE0B1BQ38685564-D34AD308-0073-4F3D-9A49-5661E2854F9DQ38806954-3DF689FC-5C9F-473F-8339-C9879EEE6DB8Q38972180-EC52282E-7FAE-424D-82B3-633C350D5312Q39868791-C376A9FD-E953-4F89-B3B7-36DBE59C9321Q39968802-7FD27BAE-6193-471B-9062-B61D56220C79Q40026950-DB170E91-3E2C-4C5C-8474-60F3CA0D72FFQ40072990-A1EAEF18-C821-4B32-BC40-43317A3D0407Q40081979-F2636812-9676-4FB8-8B8E-258AB8520265Q40124392-E172884F-FC10-4299-B8F0-6A3B13BD11CCQ40238687-6BE393D5-874B-4EB2-AE65-3CD5B10E5718Q40263158-4DBC748D-EC3B-4C33-A483-4CE471FCCF01Q40534129-D80B2A5E-FFAD-435F-8F57-9C1873225C39Q40730536-DF87E3BA-41B1-465A-A1EF-2EA1F30A4FABQ40741855-189C9FA9-B041-4DD7-A468-2D0C2F00726AQ40810821-3C57CC6D-0EE6-47C9-B3E5-551FE8E06C0EQ41703167-9ED9D9E9-BE2E-4577-8030-BBA876733635Q41870626-0363BF68-F392-4D07-AC03-9B4273C196C4Q41924669-B4DE265B-1350-4053-B9DB-455C1C1EDB75Q42209453-699A3ED6-DFA7-40C6-B721-AEA69CCA88F8Q42249962-B6815E19-E606-495A-BA00-C728370F00E2Q42251200-A78DA934-EFF7-4B45-A94C-28C2E87A5C9D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vincenza Calvaruso
@ast
Vincenza Calvaruso
@en
Vincenza Calvaruso
@es
Vincenza Calvaruso
@nl
Vincenza Calvaruso
@sl
type
label
Vincenza Calvaruso
@ast
Vincenza Calvaruso
@en
Vincenza Calvaruso
@es
Vincenza Calvaruso
@nl
Vincenza Calvaruso
@sl
prefLabel
Vincenza Calvaruso
@ast
Vincenza Calvaruso
@en
Vincenza Calvaruso
@es
Vincenza Calvaruso
@nl
Vincenza Calvaruso
@sl
P106
P1153
25632063300
P21
P31
P3835
vincenza-calvaruso
P496
0000-0002-0287-1059